263 related articles for article (PubMed ID: 17089217)
1. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
Thomas JA; Jacobs S; Kierstein J; Van Hove J
J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with laronidase (Aldurazyme
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009354. PubMed ID: 31211405
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
[TBL] [Abstract][Full Text] [Related]
7. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
[TBL] [Abstract][Full Text] [Related]
8. Laronidase.
BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
[TBL] [Abstract][Full Text] [Related]
9. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
10. Laronidase treatment of mucopolysaccharidosis I.
Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue Y; Richards SM; Mahmood A; Cox GF
Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
[TBL] [Abstract][Full Text] [Related]
13. 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I.
Pjetraj D; Santoro L; Sgattoni C; Padella L; Zampini L; Monachesi C; Gabrielli O; Catassi C
Am J Med Genet A; 2023 Feb; 191(2):564-569. PubMed ID: 36333985
[TBL] [Abstract][Full Text] [Related]
14. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.
Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV
BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916
[TBL] [Abstract][Full Text] [Related]
15. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.
Al-Sannaa NA; Bay L; Barbouth DS; Benhayoun Y; Goizet C; Guelbert N; Jones SA; Kyosen SO; Martins AM; Phornphutkul C; Reig C; Pleat R; Fallet S; Ivanovska Holder I
Orphanet J Rare Dis; 2015 Oct; 10():131. PubMed ID: 26446585
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy in mucopolysaccharidosis type I.
Miebach E
Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
[TBL] [Abstract][Full Text] [Related]
17. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
[TBL] [Abstract][Full Text] [Related]
18. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient.
Soutar RL; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Aug; 29(4):590. PubMed ID: 16830264
[TBL] [Abstract][Full Text] [Related]
19. Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.
Gonzalez EA; Visioli F; Pasqualim G; de Souza CFM; Marinho DR; Giugliani R; Matte U; Baldo G
Clin Exp Ophthalmol; 2020 Apr; 48(3):334-342. PubMed ID: 31925897
[TBL] [Abstract][Full Text] [Related]
20. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
